

Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations:None

PI Accessory Mutations:None

PR Other Mutations:

T12S100%  
seen=1,830

•

I15V94%  
seen=1,360

•

L19V100%  
seen=3,958

•

M36I100%  
seen=4,217

•

N37D100%  
seen=8,217

•

R41K100%  
seen=4,338

•

L63Q10%  
seen=1,704

•

K70R100%  
seen=1,667

•

V82VI1,71%  
seen=2,889

Protease Inhibitors

atazanavir/r (ATV/r)

Susceptible

darunavir/r (DRV/r)

Susceptible

fosamprenavir/r (FPV/r)

Susceptible

indinavir/r (IDV/r)

Susceptible

lopinavir/r (LPV/r)

Susceptible

nelfinavir (NFV)

Susceptible

saquinavir/r (SQV/r)

Susceptible

tipranavir/r (TPV/r)

Susceptible

PR comments

Other

- V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses.

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations:None

NNRTI Mutations:

E138G100%  
seen=2,238

•

Y188L100%  
seen=8,278

RT Other Mutations:

V35T100%  
seen=1,817

•

E36A100%  
seen=1,877

•

T39A100%  
seen=1,888

•

S48T100%  
seen=1,870

•

K122E10%  
seen=1,702

•

D123G100%  
seen=1,701

•

D177E10%  
seen=1,178

•

I178L100%  
seen=1,162

•

G196E10%  
seen=1,298

•

Q207E100%  
seen=1,172

•

R211K10%  
seen=1,138

•

F214L100%  
seen=1,302

•

E224K10%  
seen=1,381

•

V245Q100%  
seen=1,208

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC)

Susceptible

zidovudine (AZT)

Susceptible

stavudine (D4T)

Susceptible

didanosine (DDI)

Susceptible

emtricitabine (FTC)

Susceptible

lamivudine (3TC)

Susceptible

tenofovir (TDF)

Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

High-Level Resistance

efavirenz (EFV)

High-Level Resistance

etravirine (ETR)

Low-Level Resistance

nevirapine (NVP)

High-Level Resistance

rilpivirine (RPV)

High-Level Resistance

RT comments

NNRTI

- E138Q/G are non-polymorphic accessory mutations selected by ETR occasionally NVP and EFV. They cause low-level reductions in susceptibility to NVP, RPV, and ETR.
- Y188L is a non-polymorphic mutation that confers high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for NRTI.

Drug resistance mutation scores of NNRTI:

Download CSV

Rule	DOR ↕	EFV ↕	ETR ↕	NVP ↕	RPV ↕
<a href="#">Y188L</a>	60	60	10	60	60
<a href="#">E138G</a>	0	10	10	10	15
Total	60	70	20	70	75

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations:None

INSTI Accessory Mutations:None

IN Other Mutations:

KTR100%  
seen=112

•

S17N100%  
seen=188

•

M50L100%  
seen=184

•

I72V100%  
seen=98

•

T112W1,71%  
seen=128

•

I113V100%  
seen=118

•

T124A100%  
seen=121

•

T125A100%  
seen=121

•

D167DE1,71%  
seen=128

•

F181L100%  
seen=97

•

V201I100%  
seen=138

•

I204L100%  
seen=141

•

K211Q100%  
seen=112

•

L234I100%  
seen=141

•

V249I100%  
seen=131

•

D256E100%  
seen=132

Integrase Strand Transfer Inhibitors

bictegravir (BIC)

Susceptible

cabotegravir (CAB)

Susceptible

dolutegravir (DTG)

Susceptible

elvitegravir (EVG)

Susceptible

raltegravir (RAL)

Susceptible

Mutation scoring: IN

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for INSTI.